Phaeohyphomycosis due to dematiaceous fungi; a review of the literature

Journal of Mazandaran University of Medical Sciences

Volumn 22, Issue 92, 2012, Pages 99-126

  Afsarian, Mohammad Hosein ^a,b   Shokohi, Tahereh ^a   Arzanlou, Mehdi ^c   Sarvtin, Mehdi Taheri ^d   Badali, Hamid ^a  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b FASA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF TABRIZ   (Iran)

^d MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antifungal therapy; Black yeast; Melanized fungi; Phaeohyphomycosis

Indexed keywords

ITRACONAZOLE; POSACONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; CELL INVASION; CHAETOTHYRIALES; CHROMOMYCOSIS; CLADOPHIALOPHORA; COMPUTER ASSISTED TOMOGRAPHY; EXOPHIALA; FUNGUS; MICROSCOPY; NONHUMAN; PHAEOHYPHOMYCOSIS; POLYMERASE CHAIN REACTION; RADIOGRAPHY; REVIEW;

EID: 84978285752     PISSN: 17359279     EISSN: 17359260     Source Type: Journal    
DOI: None     Document Type: Review

References (211)

1. Adam RD, Paquin ML, Petersen EA, Saubolle MA, Rinaldi MG, Corcoran JG, et al. Phaeohyphomycosis caused by the fungal genera Bipolaris and Exserohilum. A report of 9 cases and review of the literature. Medicine 1986; 65(4): 203-217.
2. Andes D, Proctor R, Bush RK, Pasic TR. Report of successful prolonged antifungal therapy for refractory allergic fungal sinusitis. Clin Infect Dis 2000; 31(1): 202-204.
3. Elgart GW. Chromoblastomycosis. Dermatol Clin 1996; 14: 77-83.
4. Fernanda Silveira and Marcio Nucci. Emergence of black moulds in fungal disease: epidemiology and therapy. Curr Opin Infect Dis 2001; 14(6): 679-684.
5. Rossmann SN, Cernoch PL, Davis JR. Dematiaceous fungi are an increasing cause of human disease. Clin Infect Dis 1996; 22(1): 73-80.
6. Rinaldi MG. Phaeohyphomycosis. Dermatol Clin 1996; 14(1): 147-153.
7. Bloomfield BJ, Alexander M. Melanins and resistance of fungi to lysis. J Bacteriol 1967; 93(4): 1276-1280.
8. Revankar SG, Sutton DA. Melanized Fungi in Human Disease. J Clin Microbiol Rew 2010; 23(4): 884-928.
9. Ben-Ami R, Lewis RE, Raad II, Kontoyiannis DP. Phaeohyphomycosis in a tertiary care cancer center. Clin Infect Dis 2009; 48(8): 1033-1041.
10. Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population-based laboratory active surveillance. Clin Infect Dis 1998; 27(5): 1138-1147.
11. Revankar SG, Sutton DA, Rinaldi MG. Primary central nervous system phaeohyphomycosis: a review of 101 cases. Clin Infect Dis 2004; 38(2): 206-216.
12. Revankar SG, Patterson JE, Sutton DA, Pullen R, Rinaldi MG. Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin Infect Dis 2002; 34(4): 467-476.
13. Pang KR, Wu JJ, Huang DB, Tyring SK. Subcutaneous fungal infections. Dermatol Ther 2004; 17(6): 523-531.
14. De Hoog GS, Guarro J, Gene J, Figueras MJ. Atlas of clinical fungi. Utrecht, Netherlands: Centraalbureau voor Schimmelcultures. 2000.
15. De Hoog GS, Guarro J, Gene J, Fígueras MJ. Atlas of clinical fungi, pilot version of 3rd ed. CD-ROM. Baarn, Netherlands: Centraalbureau voor Schimmelcultures; 2009.
16. Vincente VA, Attili-Angelis D, Pie MR, Queiroz-Telles F, Cruz LM, Najafzadeh MJ, et al. Environmental isolation of black yeastlike fungi involved in human infection. Stud Mycol 2008; 61: 137-144.
17. Emmens RK, Richardson D, Thomas W, Hunter S, Hennigar RA, Wingard JR, et al. Necrotizing cerebritis in an allogeneic bone marrow transplant recipient due to Cladophialophora bantiana. J Clin Microbiol 1996; 34(5): 1330-1332.
18. Badali H, Chander J, Seyedmousavi S, Sidhu S, Rani H, Attri A, et al. Multiple subcutaneous cysts due to Exophiala spinifera in an immunocompetent patient. Med Mycol 2012; 50(2): 207-213.
19. Badali H, Chander J, Bansal S, Aher A, Borkar SS, Meis JF, et al. First autochthonous case of Rhinocladiella mackenziei cerebral abscess outside the Middle East. J Clin Microbiol 2010; 48(2): 646-649.
20. Kaltseis J, Rainer J, De Hoog GS. Ecology of Pseudallescheria and Scedosporium species in human-dominated and natural environments and their distribution in clinical samples. Med Mycol 2009; 47(4): 398-405.
21. Crous PW, Braun U, Schubert K, Groenewald JZ. Delimiting Cladosporium from morphologically similar genera. Stud Mycol 2007; 58: 33-56.
22. De Hoog GS, Horre R. Molecular taxonomy of the Alternaria and Ulocladium species from humans and their identification in the routine laboratory. Mycoses 2002; 45(8): 259-276.
23. Shelton BG, Kirkland KH, Flanders WD, Morris GK. Profiles of airborne fungi in buildings and outdoor environments in the United States. Appl Environ Microbiol 2002; 68(4): 1743-1753.
24. Badali H, Gueidan C, Najafzadeh MJ, Bonifaz A, van den Ende AH, de Hoog GS. Biodiversity of the genus Cladophialophora. Stud Mycol 2008; 61: 175-191.
25. Badali H, Carvalho VO, Vicente V, Attili-Angelis D, Kwiatkowski IB, Gerrits Van Den Ende AH, et al. Cladophialophora saturnica sp. nov., a new opportunistic species of Chaetothyriales revealed using molecular data. Med Mycol 2009; 47(1): 51-62.
26. Centers for Disease Control and Prevention. Exophiala infection from contaminated injectable steroids prepared by a compounding pharmacy-United States. Morb Mortal Wkly Rep 2002; 51(49): 1109-1112.
27. Chabasse D, de Bievre C, Legrand E, Saint-Andre JP, de Gentile L, Cimon B, et al. Subcutaneous abscess caused by Pleurophomopsis lignicola Petr: first case. J Med Vet Mycol 1995; 33(6): 415-417.
28. Chander J, Singla N, Agnihotri N, Arya SK, Deep A. Keratomycosis in and around Chandigarh: a five-year study from a north Indian tertiary care hospital. Indian J Pathol Microbiol 2008; 51(2): 304-306.
29. Yurlova NA, de Hoog GS Exopolysaccharides and capsules in human pathogenic Exophiala species. Mycoses 2002; 45(11-12): 443-448.
30. Sterflinger K. Temperature and NaCltolerance of rock-inhabiting meristematic fungi. Antonie van Leeuwenhoek 1998; 74(4): 271-281.
31. Chandramukhi A, Ramadevi MG, Shankar SK. Cerebral cladosporiosis—a neuropathological and microbiological study. Clin Neurol Neurosurg 1983; 85(4): 245-253.
32. de Hoog GS, Zeng JS, Harrak MJ, Sutton DA. Exophiala xenobiotica sp. Nov., an opportunistic black yeast inhabiting environments rich in hydrocarbons. Antonie van Leeuwenhoek 2006; 90(3): 257-268.
33. Paolo WF, Dadachova Jr. E, Mandal P, Casadevall A, Szaniszlo PJ, Nosanchuk JD. Effects of disrupting the polyketide synthase gene WdPKS1 in Wangiella [Exophiala] dermatitidis on melanin production and resistance to killing by antifungal compounds, enzymatic degradation, and extremes in temperature. BMC Microbiol 2006; 19(6): 55.
34. Masini T, Riviera L, Cappricci E, Arienta C. Cerebral phaeohyphomycosis. Clin Neuropathol 1985; 4(6): 246-249.
35. McGinnis MR. Mycetoma. Dermatol Clin 1996; 14(1): 97-104.
36. Ahmed AO, van Leeuwen W, Fahal A, van de Sande W, Verbrugh H, van Belkum A. Mycetoma caused by Madurella mycetomatis: a neglected infectious burden. Lancet Infect Dis 2004; 4(9): 566-574.
37. Badali H, Najafzadeh MJ, Van Esbroeck M, van den Enden E, Tarazooie B, Meis JF, et al. The clinical spectrum of Exophiala jeanselmei, with a case report and in vitro antifungal susceptibility of the species. Med Mycol 2010; 48(2): 318-327.
38. Badali HU, Bonifaz A, Barrón-Tapia T, Vázquez-González D, Estrada-Aguilar L, Cavalcante Oliveira NM, et al. Rhinocladiella aquaspersa, proven agent of verrucous skin infection and a novel type of chromoblastomycosis. Med Mycol 2010; 48(5): 696-703.
39. Queiroz-Telles F, Esterre P, Perez-Blanco M, Vitale RG, Salgado CG, Bonifaz A. Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment. Med Mycol 2009; 47(1): 3-15.
40. Burns KE, Ohori NP, Iacono AT. Dactylaria gallopava infection presenting as a pulmonary nodule in a single-lung transplant recipient. J Heart Lung Transplant 2000; 19(9): 900-902.
41. Lin RY, Williams KD. Hypersensitivity to molds in New York City in adults who have asthma. Allergy Asthma Proc 2003; 24(1): 13-18.
42. O’Driscoll BR, Hopkinson LC, Denning DW. Mold sensitization is common amongst patients with severe asthma requiring multiple hospital admissions. BMC Pulm Med 2005; 18(5): 4.
43. Neukirch C, Henry C, Leynaert B, Liard R, Bousquet J, Neukirch F. Is sensitization to Alternaria alternata a risk factor for severe asthma? A population-based study. J Allergy Clin Immunol 1999; 103(4): 709-711.
44. Schubert MS. Allergic fungal sinusitis: pathophysiology, diagnosis and management. Med Mycol 2009; 47(Suppl 1): S324-S330.
45. Ferguson BJ. Definitions of fungal rhinosinusitis. Otolaryngol Clin N Am 2000; 33(2): 227-235.
46. Bartynski JM, McCaffrey TV, Frigas E. Allergic fungal sinusitis secondary to dermatiaceous fungi—Curvularia lunata and Alternaria.Otolaryngol. Head Neck Surg 1990; 103(1): 32-39.
47. Noble JA, Crow SA, Ahearn DG, Kuhn FA. Allergic fungal sinusitis in the southeastern U.S.A.: involvement of a new agent Epicoccum nigrum Ehrenb. ex Schlecht. 1824. J Med Vet Mycol 1997; 35(6): 405-409.
48. Sasama J, Sherris DA, Shin SH, Kephart GM, Kern EB, Ponikau JU. New paradigm for the roles of fungi and eosinophils in chronic rhinosinusitis. Curr Opin Otolaryngo. Head Neck Surg 2005; 13(1): 2-8.
49. Houser SM, Corey JP. Allergic fungal rhinosinusitis: pathophysiology, epidemiology, and diagnosis. Otolaryngol Clin N Am 2000; 33(2): 399-409.
50. McAleer R, Kroenert DB, Elder JL, Froudist JH. Allergic bronchopulmonary disease caused by Curvularia lunata and Drechslera hawaiiensis. Thorax 1981; 36(5): 338-344.
51. Rinaldi MG, Phillips P, Schwartz JG, Winn RE, Holt GR, Shagets FW, et al. Human Curvularia infections. Report of five cases and review of the literature. Diagn Microbiol Infect Dis 1987; 6(1): 27-39.
52. Taj-Aldeen SJ, Hilal AA, Schell WA. Allergic fungal rhinosinusitis: a report of 8 cases. Am J Otolaryngol 2004; 25(3): 213-218.
53. Kuhn FA, Javer AR. Allergic fungal rhinosinusitis: perioperative management, prevention of recurrence, and role of steroids and antifungal agents. Otolaryngol Clin N Am 2000; 33(2): 419-433.
54. Rupa V, Jacob M, Mathews MS, Job A, Kurien M, Chandi SM. Clinicopathological and mycological spectrum of allergic fungal sinusitis in South India. Mycoses 2002; 45(9-10): 364-367.
55. Chan KO, Genoway KA, Javer AR. Effectiveness of itraconazole in the management of refractory allergic fungal rhinosinusitis. J Otolaryngol Head Neck Surg 2008; 37(6): 870-874.
56. Seiberling K, Wormald PJ. The role of itraconazole in recalcitrant fungal sinusitis. Am J Rhinol Allergy 2009; 23(3): 303-306.
57. Erwin GE, Fitzgerald JE. Case report: allergic bronchopulmonary aspergillosis and allergic fungal sinusitis successfully treated with voriconazole. J Asthma 2007; 44(10): 891-895.
58. Brummund W, Kurup VP, Harris GJ, Duncavage JA, Arkins JA. Allergic sinoorbital mycosis. A clinical and immunologic study. JAMA 1986; 256(23): 3249-3253.
59. Colton R, Zeharia A, Karmazyn B, Buller N, Levy Y, Inbal R, et al. Exserohilum sinusitis presenting as proptosis in a healthy adolescent male. J Adolesc Health 2002; 30(1): 73-75.
60. Agarwal R. Allergic bronchopulmonary aspergillosis. Chest 2009; 135(3): 805-826.
61. Venarske DL, deShazo RD. Sinobronchial allergic mycosis: the SAM syndrome. Chest 2002; 121(5): 1670-1676.
62. Halwig JM, Brueske DA, Greenberger PA, Dreisin RB, Sommers HM. Allergic bronchopulmonary curvulariosis. Am Rev Resp Dis 1985; 132(1): 186-188.
63. Lake FR, Froudist JH, McAleer R, Gillon RL, Tribe AE, Thompson PJ. Allergic bronchopulmonary fungal disease caused by Bipolaris and Curvularia. Aust N Z J Med 1991; 21(6): 871-874.
64. Revankar SG. Dematiaceous fungi. Semin Resp Crit Care Med 2004; 25(2): 183-189.
65. Gupta AK, Ryder JE, Baran R, Summerbell RC. Non-dermatophyte onychomycosis. Dermatol Clin 2003; 21(2): 257-268.
66. Tosti A, Piraccini BM, Lorenzi S, Iorizzo M. Treatment of non-dermatophyte mold and Candida onychomycosis. Dermatol Clin 2003; 21(3): 491-497.
67. Larangeira de Almeida H. Jr, Dallazem RN, Dossantos LS, Hallal SA. Bilateral tinea nigra in a temperate climate. Dermatol Online J 2007; 13(3): 25.
68. Bonifaz A, Badali H, de Hoog GS, Cruz M, Araiza J, Cruz MA, et al. Tinea nigra by Hortaea werneckii, a report of 22 cases from Mexico. Stud Mycol 2008; 61: 77-82.
69. Perez C, Colella MT, Olaizola C, Hartung de Capriles C, Magaldi S, Mata-Essayag S. Tinea nigra: report of twelve cases in Venezuela. Mycopathologia 2005; 160(3): 235-238.
70. Bakerspigel A. The isolation of Phoma hibernica from a lesion on a leg. Sabouraudia 1970; 7(4): 261-264.
71. Costa AR, Porto E, Lacaz Cd, de Melo NT, Calux MD, Valente NY. Cutaneous and ungual phaeohyphomycosis caused by species of Chaetomium Kunze (1817) ex Fresenius, 1829. J. Med Vet Mycol 1988; 26(5): 261-268.
72. Ginarte M, Pereiro M. Jr, Fernandez-Redondo V, Toribio J. Plantar infection by Scopulariopsis brevicaulis. Dermatology 1996; 193(2): 149-151.
73. Gupta G, Burden AD, Shankland GS, Fallowfield ME, Richardson MD. Tinea nigra secondary to Exophiala werneckii responding to itraconazole. Br J Dermatol 1997; 137(3): 483-484.
74. Pastor FJ, Guarro J. Alternaria infections: laboratory diagnosis and relevant clinical features. Clin Microbiol Infect 2008; 14(8): 734-746.
75. Agger WA, Andes D, Burgess JW. Exophiala jeanselmei infection in a heart transplant recipient successfully treated with oral terbinafine. Clin Infect Dis 2004; 38(11): e112-115.
76. Chen YT, Lin HC, Huang CC, Lo YH. Cutaneous phaeohyphomycosis caused by an itraconazole and amphotericin B resistant strain of Veronaea botryosa. Int J Dermatol 2006; 45(4): 429-432.
77. De Monbrison F, Piens MA, Ample B, Euvrard S, Cochat P, Picot S. Two cases of subcutaneous phaeohyphomycosis due to Exophiala jeanselmei, in cardiac transplant and renal transplant patients. Br J Dermatol 2004; 150(3): 597-598.
78. Fernandez M, Noyola DE, Rossmann SN, Edwards MS. Cutaneous phaeohyphomycosis caused by Curvularia lunata and a review of Curvularia infections in pediatrics. Pediatr Infect Dis J 1999; 18(8): 727-731.
79. Foulet F, Duvoux C, de Bievre C, Hezode C, Bretagne S. Cutaneous phaeohyphomycosis caused by Veronaea bothryosa in a liver transplant recipient successfully treated with itraconazole. Clin Infect Dis 1999; 29(3): 689-690.
80. Fukushiro R, Udagawa S, Kawashima Y, Kawamura Y. Subcutaneous abscesses caused by Ochroconis gallopavum. J Med Vet Mycol 1986; 24(3): 175-182.
81. Gugnani HC, Ramesh V, Sood N, Guarro J, Moin Ul H, Paliwal-Joshi A, Singh B. Cutaneous phaeohyphomycosis caused by Cladosporium oxysporum and its treatment with potassium iodide. Med Mycol 2006; 44(3): 285-288.
82. Hurley MA, Saffran B. Subcutaneous phaeohyphomycosis: overview and case report. J Foot Ankle Surg 1997; 36(3): 230-235.
83. Martinez-Gonzalez MC, Verea MM, Velasco D, Sacristan F, Del Pozo J, Garcia-Silva J, Fonseca E. Three cases of cutaneous phaeohyphomycosis by Exophiala jeanselmei. Eur J Dermatol 2008; 18(3): 313-316.
84. Matsushita A, Jilong L, Hiruma M, Kobayashi M, Matsumoto T, Ogawa H, et al. Subcutaneous phaeohyphomycosis caused by Veronaea botryosa in the People’s Republic of China. J Clin Microbiol 2003; 41(5): 2219-2222.
85. O’Quinn RP, Hoffmann JL, Boyd AS. Colletotrichum species as emerging opportunistic fungal pathogens: a report of 3 cases of phaeohyphomycosis and review. J Am Acad Dermatol 2001; 45(1): 56-61.
86. Ogawa MM, Galante NZ, Godoy P, Fischman-Gompertz O, Martelli F, Colombo AL, et al. Treatment of subcutaneous phaeohyphomycosis and prospective followup of 17 kidney transplant recipients. J Am Acad Dermatol 2009; 61(6): 977-985.
87. McCown HF, Sahn EE. Subcutaneous phaeohyphomycosis and nocardiosis in a kidney transplant patient. J Am Acad Dermatol 1997; 36(5 pt 2): 863-866.
88. Flynn BJ, Bourbeau PP, Cera PJ, Scicchitano LM, Jordan RL, Yap WT. Phaeohyphomycosis of the epididymis caused by Exophiala jeanselmei. J Urol 1999; 162(2): 492-493.
89. Ara M, Aspiroz C, Zaballos P, Alcalde V, Alvarez R, Rezusta A, et al. Relapse of cutaneous Alternaria infectoria in a renal transplant recipient after 2 years. Acta Derm Venereol 2006; 86(2): 154-155.
90. Feldman DL, Fitzpatrick E, Schaening O, Lutwick LI. Nosocomial phaeomycotic cyst of the hand. Ann Plastic Surg 1995; 35(1): 113-115.
91. Diaz M, Puente R, Trevino MA. Response of long-running Alternaria alternata infection to fluconazole. Lancet 1990; 336: 513.
92. Farina C, Gotti E, Mouniee D, Boiron P, Goglio A. Phaeoacremonium parasiticum subcutaneous infection in a kidney-transplanted patient successfully treated by surgery. Transpl Infect Dis 2007; 9(3): 253-255.
93. Bogle MA, Rabkin MS, Joseph AK. Mohs micrographic surgery for the eradication of phaeohyphomycosis of the hand. Dermatol Surg 2004; 30(2): 231-233.
94. Miele PS, Levy CS, Smith MA, Dugan EM, Cooke RH, Light JA, et al. Primary cutaneous fungal infections in solid organ transplantation: a case series. Am J Transplant 2002; 2(7): 678-683.
95. Gilmour TK, Rytina E, O’Connell PB, Sterling JC. Cutaneous alternariosis in a cardiac transplant recipient. Australas J Dermatol 2001; 42(1): 46-49.
96. Gopinathan U, Garg P, Fernandes M, Sharma S, Athmanathan S, Rao GN. The epidemiological features and laboratory results of fungal keratitis: a 10-year review at a referral eye care center in South India. Cornea 2002; 21(6): 555-559.
97. Srinivasan M. Fungal keratitis. Curr Opin Ophthalmol 2004; 15(4): 321-327.
98. Durkin SR, Henderson T, Raju R, Ellis D. Successful treatment of phaeohyphomycotic keratitis caused by Bipolaris australiensis. Clin Exp Ophthalmol 2008; 36(7): 697-699.
99. Bharathi MJ, Ramakrishnan R, Vasu S, Meenakshi R, Palaniappan R. Epidemiological characteristics and laboratory diagnosis of fungal keratitis. A three-year study. Indian J Ophthalmol 2003; 51(4): 315-321.
100. Peerapur BV, Rao SD, Patil S, Mantur BG. Keratomycosis due to Exserohilum rostratum—a case report. Indian J Med Microbiol 2004; 22(2): 126-127.
101. Wilhelmus KR, Jones DB. Curvularia keratitis. Trans Am Ophthalmol Soc 2001; 99: 111-130.
102. Iyer SA, Tuli SS, Wagoner RC. Fungal keratitis: emerging trends and treatment outcomes. Eye Contact Lens 2006; 32(6): 267-271.
103. Jurkunas U, Behlau I, Colby K. Fungal keratitis: changing pathogens and risk factors. Cornea 2009; 28(6): 638-643.
104. Dupuis A, Tournier N, Le Moal G, Venisse N. Preparation and stability of voriconazole eye drop solution. Antimicrob. Agents Chemother 2009; 53(2): 798-799.
105. Harkness B, Andresen D, Kesson A, Isaacs D. Infections following lawnmower and farm machinery-related injuries in children. J Paediatr Child Health 2009; 45(9): 525-528.
106. Kesson AM, Bellemore MC, O’Mara TJ, Ellis DH, Sorrell TC. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with a novel agent, hexadecylphospocholine (miltefosine), in combination with terbinafine and voriconazole: a case report. Clin Infect Dis 2009; 48(9): 1257-1261.
107. Malekzadeh M, Overturf GD, Auerbach SB, Wong L, Hirsch M. Chronic, recurrent osteomyelitis caused by Scedosporium inflatum. Pediatr Infect Dis J 1990; 9(5): 357-359.
108. Karuppal R, Kumaran CM, Marthya A, Manoj Kumar CV, Narayanan MP, Raman RV, et al. Tibial osteomyelitis due to Fonsecaea pedrosoi in an immunocompetent patient: case report. J Foot Ankle Surg 2009; 48(5): 569-572.
109. Menon S, Edwards JC. Mycotic arthritis of the knee due to Madurella grisea. Br J Rheumatol 1994; 33(3): 292-295.
110. Bava AJ, Fayad A, Cespedes C, Sandoval M. Fungal peritonitis caused by Bipolaris spicifera. Med Mycol 2003; 41(6): 529-531.
111. Buchanan WE, Quinn MJ, Hasbargen JA. Peritoneal catheter colonization with Alternaria: successful treatment with catheter preservation. Perit Dial Int 1994; 14(1): 91-92.
112. Canon HL, Buckingham SC, Wyatt RJ, Jones DP. Fungal peritonitis caused by Curvularia species in a child undergoing peritoneal dialysis. Pediatr Nephrol 2001.16(1): 35-37.
113. Caporale NE, Calegari L, Perez D, Gezuele E. Peritoneal catheter colonization and peritonitis with Aureobasidium pullulans. Perit Dial Int 1996; 16(1): 97-98.
114. Greig J, Harkness M, Taylor P, Hashmi C, Liang S, Kwan J. Peritonitis due to the dermatiaceous mold Exophiala dermatitidis complicating continuous ambulatory peritoneal dialysis. Clin Microbiol Infect 2003; 9(7): 713-715.
115. Robson AM, Craver RD. Curvularia urinary tract infection: a case report. Pediatr Nephrol 1994; 8(1): 83-84.
116. Kerkmann ML, Piontek K, Mitze H, Haase G. Isolation of Exophiala (Wangiella) dermatitidis in a case of otitis externa. Clin Infect Dis 1999; 29(4): 939-940.
117. Lasala PR, Smith MB, McGinnis MR, Sackey K, Patel JA, Qiu S. Invasive Exserohilum sinusitis in a patient with aplastic anemia. Pediatr Infect Dis J 2005; 24(10): 939-941.
118. Al-Aidaroos A, Bin-Hussain I, El Solh H, Kofide A, Thawadi S, Belgaumi A, et al. 2007. Invasive Chaetomium infection in two immunocompromised pediatric patients. Pediatr Infect Dis J 26(5): 456-458.
119. Diemert D, Kunimoto D, Sand C, Rennie R. Sputum isolation of Wangiella dermatitidis in patients with cystic fibrosis. Scand J Infect Dis 2001; 33(10): 777-779.
120. Elinav H, Izhar U, Benenson S, Admon D, Hidalgo-Grass C, Polacheck I, Korem M. Invasive Scytalidium dimidiatum infection in an immunocompetent adult. J Clin Microbiol 2009; 47(4): 1259-1263.
121. Hollingsworth JW, Shofer S, Zaas A. Successful treatment of Ochroconis gallopavum infection in an immunocompetent host. Infection 2007; 35(5): 367-369.
122. Garcia-Ruiz JC, Amutio E, Hernandez I, Alvarez C, Floristan F, Zuazua I, et al. Clinical resolution of Scedosporium prolificans pneumonia associated with treatment with liposomal amphotericin B in a patient with acute leukemia. Rev Iberoam Micol 1998; 15(3): 158-159.
123. Lastoria C, Cascina A, Bini F, Di Matteo A, Cavanna C, Farina C, et al. Pulmonary Cladophialophora boppii infection in a lung transplant recipient: case report and literature review. J Heart Lung Transplant 2009; 28(6): 635-637.
124. Mullane K, Toor AA, Kalnicky C, Rodriguez T, Klein J, Stiff P. Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections. Transpl Infect Dis 2007; 9(2): 89-96.
125. Singh N, Agarwal R, Gupta D, Shivaprakash MR, Chakrabarti A. An unusual case of mediastinal mass due to Fonsecaea pedrosoi. Eur Respir J 2006; 28(3): 662-664.
126. Ajanee N, Alam M, Holmberg K, Khan J. Brain abscess caused by Wangiella dermatitidis: case report. Clin Infect Dis 1996; 23(1): 197-198.
127. Arunkumar MJ, Rajshekhar V, Chandy MJ, Thomas PP, Jacob CK. Management and outcome of brain abscess in renal transplant recipients. Postgrad Med J 2000; 76(894): 207-211.
128. Bhatia R, Tandon P, Misra NK. Inflammatory lesions of the basal ganglia and thalamus: review of twenty-one cases. Neurosurgery 1986; 19(6): 983-988.
129. Dastur HM, Chaukar AP, Rebello MD. Cerebral chromoblastomycosis due to Cladosporium trichoides (bantianum). I. A review and case report. Neurol. India 1966; 14(1): 1-5.
130. Guppy KH, Thomas C, Thomas K, Anderson D. Cerebral fungal infections in the immunocompromised host: a literature review and a new pathogen—Chaetomium atrobrunneum: case report. Neurosurgery 1998; 43(6): 1463-1469.
131. Harrison DK, Moser S, Palmer CA. Central nervous system infections in transplant recipients by Cladophialophora bantiana. South Med J 2008; 101(3): 292-296.
132. Hart AP, Sutton DA, McFeeley PJ, Kornfeld M. Cerebral phaeohyphomycosis caused by a dematiaceous Scopulariopsis species. Clin Neuropathol 2001; 20(5): 224-228.
133. Horré R, De Hoog GS. Primary cerebral infections by melanized fungi: a review. Stud Mycol 1999; 43: 176-193.
134. Kanj SS, Amr SS, Roberts GD. Ramichloridium mackenziei brain abscess: report of two cases and review of the literature. Med Mycol 2001; 39(1): 97-102.
135. Lirng JF, Tien RD, Osumi AK, Madden JF, McLendon RP, Sexton D. Cerebral phaeohyphomycosis complicated with brain abscess: a case report. Chin Med J 1995; 55(6): 491-495.
136. Osiyemi OO, Dowdy LM, Mallon SM, Cleary T. Cerebral phaeohyphomycosis due to a novel species: report of a case and review of the literature. Transplantation 2001; 71(9): 1343-1346.
137. Dong Ming Li, Sybren de Hoog G. Cerebral phaeohyphomycosis—a cure at what lengths? Lancet Infect Dis 2009; 9(6): 376-383.
138. Garg N, Devi IB, Vajramani GV, Nagarathna S, Sampath S, Chandramouli BA, Chandramuki A, Shankar SK. Central nervous system cladosporiosis: an account of ten culture-proven cases. Neurol India 2007; 55(3): 282-288.
139. Huttova M, Kralinsky K, Horn J, Marinova I, Iligova K, Fric J, et al. Prospective study of nosocomial fungal meningitis in children—report of 10 cases. Scand J Infect Dis 1998; 30(5): 485-487.
140. Al Abdely HM, Alkhunaizi AM, Al Tawfiq JA, Hassounah M, Rinaldi MG, Sutton DA. Successful therapy of cerebral phaeohyphomycosis due to Ramichloridium mackenziei with the new triazole posaconazole. Med Mycol 2005; 43(1): 91-95.
141. Alabaz D, Kibar F, Arikan S, Sancak B, Celik U, Aksaray N, et al. Systemic phaeohyphomycosis due to Exophiala (Wangiella) in an immunocompetent child. Med Mycol 2009; 47(6): 653-657.
142. Badali H, De Hoog GS, Curfs-Breuker I, Andersen B, Meis JF. In vitro activities of eight antifungal drugs against 70 clinical and environmental isolates of Alternaria species. J Antimicrob Chemother 2009; 63(6): 1295-1297.
143. Brandt ME, Warnock DW. Epidemiology, clinical manifestations, and therapy of infections caused by dematiaceous fungi. J Chemother 2003; 15(Suppl 2): 36-47.
144. Fader RC, McGinnis MR. Infections caused by dematiaceous fungi: chromoblastomycosis and phaeohyphomycosis. Infect Dis Clin North Am 1988; 2(4): 925-938.
145. Hiruma M, Kawada A, Ohata H, Ohnishi Y, Takahashi H, Yamazaki M, et al. Systemic phaeohyphomycosis caused by Exophiala dermatitidis. Mycoses 1993; 36(1-2): 1-7.
146. Cooley L, Spelman D, Thursky K, Slavin M. Infection with Scedosporium apiospermum and S. prolificans, Australia. Emerg Infect Dis 2007; 13(8): 1170-1177.
147. Grenouillet F, Botterel F, Crouzet J, Larosa F, Hicheri Y, Forel JM, et al. Scedosporium prolificans: an emerging pathogen in France? Med Mycol 2009; 47(4): 343-350.
148. Howden BP, Slavin MA, Schwarer AP, Mijch AM. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis 2003; 22(2): 111-113.
149. Idigoras P, Perez-Trallero E, Pineiro L, Larruskain J, Lopez-Lopategui MC, Rodriguez N, et al. Disseminated infection and colonization by Scedosporium prolificans: a review of 18 cases, 1990–1999. Clin Infect Dis 2001; 32(11): e158–e165.
150. Tong SY, Peleg AY, Yoong J, Handke R, Szer J, Slavin M. Breakthrough Scedosporium prolificans infection while receiving voriconazole prophylaxis in an allogeneic stem cell transplant recipient. Transpl Infect Dis 2007; 9(3): 241-243.
151. Whyte M, Irving H, O’Regan P, Nissen M, Siebert D, Labrom R. Disseminated Scedosporium prolificans infection and survival of a child with acute lymphoblastic leukemia. Pediatr Infect Dis J 2005; 24(4): 375-377.
152. Hong KH, Kim JW, Jang SJ, Yu E, Kim EC. Liver cirrhosis caused by Exophiala dermatitidis. J Med Microbiol 2009; 58(pt 5): 674-677.
153. Al-Obaid I, Ahmad S, Khan ZU, Dinesh B, Hejab HM. Catheter-associated fungemia due to Exophiala oligosperma in a leukemic child and review of fungemia cases caused by Exophiala species. Eur J Clin Microbiol Infect Dis 2006; 25(11): 729-732.
154. Boggild AK, Poutanen SM, Mohan S, Ostrowski MA. Disseminated phaeohyphomycosis due to Ochroconis gallopavum in the setting of advanced HIV infection. Med Mycol 2006; 44(8): 777-782.
155. Heath CH, Lendrum JL, Wetherall BL, Wesselingh SL, Gordon DL. Phaeoacremonium parasiticum infective endocarditis following liver transplantation. Clin Infect Dis 1997; 25(5): 1251-1252.
156. Negroni R, Helou SH, Petri N, Robles AM, Arechavala A, Bianchi MH. Case study: posaconazole treatment of disseminated phaeohyphomycosis due to Exophiala spinifera. Clin Infect Dis 2004; 38(3): e15–e20.
157. Bouza E, Munoz P, Vega L, Rodriguez-Creixems M, Berenguer J, Escudero A. Clinical resolution of Scedosporium prolificans fungemia associated with reversal of neutropenia following administration of granulocyte colony-stimulating factor. Clin Infect Dis 1996; 23(1): 192-193.
158. McGinnis MR, Padhye AA. Fungi causing eumycotic mycetoma. In Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, (ed.). Manual of clinical microbiology. 8th ed. Washington, DC: ASM Press; 2003. p. 1848-1856.
159. Centers for Disease Control and Prevention. Biosafety in microbiological and biomedical laboratories, 5th ed. Atlanta, GA: Centers for Disease Control and Prevention; 2009. p. 170-177.
160. European Economic Community. Directive 2000/54/EC. In Official journal of the European Communities. Luxembourg: Office for Official Publications of the European Communities; 2000. p. 19.
161. Ruchel R, Schaffrinski M, Seshan KR, Cole GT. Vital staining of fungal elements in deep-seated mycotic lesions during experimental murine mycoses using the parenterally applied optical brightener Blankophor. Med Mycol 2000; 38(3): 231-237.
162. Harrington BJ, Hageage GJ. Calcofluor white: a review of its uses and applications in clinical mycology and parasitology. Lab Med 2003; 34: 361-367.
163. LaRocco MT. Reagents, stains, and media: mycology. In: Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA, (ed.). Manual of clinical microbiology. 9th ed. Washington, DC: ASM Press; 2007. p. 1737-1744.
164. Crous PW, Gams W, Wingfield MJ, van Wyk PS. Phaeoacremonium gen. Nov. Associated with wilts and decline disease of woody hosts and human infections. Mycologia 1996; 88: 786-796.
165. Schnadig VJ, Woods GL. Histology of fungal infections. In: Anaissie EJ, McGinnis MR, Pfaller MA, (ed.). Clinical mycology. 2nd ed. Philadelphia PA.: Churchill Livingstone; 2009. p.79–108.
166. Kimura M, McGinnis MR. Fontana-Massonstained tissue from culture-proven mycoses. Arch Pathol Lab Med 1998; 122(12): 1107-1111.
167. Labarca JA, Wagar EA, Grasmick AE, Kokkinos HM, Bruckner DA. Critical evaluation of 4-week incubation for fungal cultures: is the fourth week useful? J Clin Microbiol 1998; 36(12): 3683-3685.
168. Cuetara MS, Alhambra A, Moragues MD, Gonzalez-Elorza E, Ponton J, Del Palacio A. Detection of (1,3)-beta-D-glucan as an adjunct to diagnosis in a mixed population with uncommon proven invasive fungal diseases or with an unusual clinical presentation. Clin Vaccine Immunol 2009; 16(3): 423-426.
169. Koo S, Bryar JM, Page JH, Baden LR, Marty FM. Diagnostic performance of the (1,3)-beta-D-glucan assay for invasive fungal disease. Clin Infect Dis 2009; 49(11): 1650-1659.
170. Lau A, Chen S, Sorrell T, Carter D, Malik R, Martin P, Halliday C. Development and clinical application of a panfungal PCR assay to detect and identify fungal DNA in tissue specimens. J Clin Microbiol 2007; 45(2): 380-385.
171. Vollmer T, Stormer M, Kleesiek K, Dreier J. Evaluation of novel broad-range real-time PCR assay for rapid detection of human pathogenic fungi in various clinical specimens. J Clin Microbiol 2008; 46(6): 1919-1926.
172. Badali H, de Hoog GS, Curfs-Breuker I, Klaassen CH, Meis JF. Use of Amplified Fragment Length Polymorphism To Identify 42 Cladophialophora Strains Related to Cerebral Phaeohyphomycosis with In Vitro Antifungal Susceptibility. J Clin Microbiol 2010 48(7): 2350-2356.
173. National Committe for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. Wayne, PA.: National Committe for Clinical Laboratory Standards; 1997.
174. Clinical Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of conidiumforming filamentous fungi. Revised M38-A2. Wayne, PA.: Clinical Laboratory Standards Institute, 2008.
175. Clinical Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A3, 3rd ed. Wayne, PA.: Clinical Laboratory Standards Institute, 2008.
176. Badali H, de Hoog GS, Curfs-Breuker I, Meis JF. In vitro activities of antifungal drugs against Rhinocladiella mackenziei, an agent of fatal brain infection. J Antimicrob Chemother 2010; 65(1): 175-177.
177. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Garcia-Effron G, Monzon A, Rodriguez-Tudela JL. In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi. Antimicrob. Agents Chemother 2005; 49(12): 5136-5138.
178. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Buitrago MJ, Monzon A, Rodriguez-Tudela JL. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob. Agents Chemother. 2006; 50(3): 917-921.
179. Cuenca-Estrella M, Ruiz-Diez B, Martinez-Suarez JV, Monzon A, Rodriguez-Tudela JL. Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother 1999; 43(1): 149-151.
180. Espinel-Ingroff A. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36(10): 2950-2956.
181. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 2001; 39(3): 954-958.
182. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 2003; 20(4): 121-136.
183. Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 2001; 150(3): 101-115.
184. Fothergill AW, Rinaldi MG, Sutton DA. Antifungal susceptibility testing of Exophiala spp.: a head-to-head comparison of amphotericin B, itraconazole, posaconazole and voriconazole. Med Mycol 2009; 47(1): 41-43.
185. Garcia-Effron G, Gomez-Lopez A, Mellado E, Monzon A, Rodriguez-Tudela JL, Cuenca-Estrella M. In vitro activity of terbinafine against medically important non-dermatophyte species of filamentous fungi. J Antimicrob Chemother 2004; 53(6): 1086-1089.
186. Gonzalez GM. In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi. Med Mycol 2009; 47(1): 71-76.
187. Gupta AK, Kohli Y. In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity. Br J Dermatol 2003; 149(2): 296-305.
188. Jessup CJ, Ryder NS, Ghannoum MA. An evaluation of the in vitro activity of terbinafine. Med Mycol 2000; 38(2): 155-159.
189. Johnson EM, Szekely A, Warnock DW. Invitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother 1998; 42(6): 741-745.
190. Johnson EM, Szekely A, Warnock DW. In vitro activity of Syn-2869, a novel triazole agent, against emerging and less common mold pathogens. Antimicrob. Agents Chemother 1999; 43(5): 1260-1263.
191. Kahn JN, Hsu MJ, Racine F, Giacobbe R, Motyl M. Caspofungin susceptibility in Aspergillus and non-Aspergillus molds: inhibition of glucan synthase and reduction of beta-D-1, 3 glucan levels in culture. Antimicrob. Agents Chemother 2006; 50(6): 2214-2216.
192. Li RK, Rinaldi MG. In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole. Antimicrob. Agents Chemother 1999; 43(6): 1401-1405.
193. McGinnis MR, Pasarell L. In vitro evaluation of terbinafine and itraconazole against dematiaceous fungi. Med Mycol 1998; 36(4): 243-246.
194. McGinnis MR, Pasarell L. In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications. J Clin Microbiol 1998; 36(8): 2353-2355.
195. Meletiadis J, Meis JF, Mouton JW, Rodriquez-Tudela JL, Donnelly JP, Verweij PE. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother 2002; 46(1): 62-68.
196. Najafzadeh MJ, Badali H, Illnait-Zaragozi MT, De Hoog GS, Meis JF. In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp. Antimicrob. Agents Chemother 2010; 54(4): 1636-1638.
197. Odabasi Z, Paetznick VL, Rodriguez JR, Chen E, Ostrosky-Zeichner L. In vitro activity of anidulafungin against selected clinically important mold isolates. Antimicrob. Agents Chemother. 2004; 48(5): 1912-1915.
198. Revankar SG. Therapy of infections caused by dematiaceous fungi. Expert Rev Anti Infect Ther 2005; 3(4): 601-612.
199. Vitale RG, Perez-Blanco M, De Hoog GS. In vitro activity of antifungal drugs against Cladophialophora species associated with human chromoblastomycosis. Med Mycol 2009; 47(1): 35-40.
200. Corrado ML, Kramer M, Cummings M, Eng RH. Susceptibility of dematiaceous fungi to amphotericin B, miconazole, ketoconazole, flucytosine and rifampin alone and in combination. Sabouraudia 1982; 20(2): 109-113.
201. Cuenca-Estrella M, Alastruey-Izquierdo A, Alcazar-Fuoli L, Bernal-Martinez L, Gomez-Lopez A, Buitrago MJ, Mellado E, Rodriguez-Tudela JL. In vitro activities of 35 double combinations of antifungal agents against Scedosporium apiospermum and Scedosporium prolificans. Antimicrob Agents Chemother 2008; 52(3): 1136-1139.
202. Gil-Lamaignere C, Roilides E, Mosquera J, Maloukou A, Walsh TJ. Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum. Antimicrob. Agents Chemother 2002; 46(7): 2234-2237.
203. Marine M, Pastor FJ, Guarro J. Combined antifungal therapy in a murine model of disseminated infection by Cladophialophora bantiana. Med Mycol 2009; 47(1): 45-49.
204. Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother 2003; 47(1): 106-117.
205. Meletiadis J, Mouton JW, Rodriguez-Tudela JL, Meis JF, Verweij PE. In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans. Antimicrob. Agents Chemother 2000; 44(2): 470-472.
206. Rodriguez MM, Calvo E, Serena C, Marine M, Pastor FJ, Guarro J. Effects of double and triple combinations of antifungal drugs in a murine model of disseminated infection by Scedosporium prolificans. Antimicrob. Agents Chemother 2009; 53(5): 2153-2155.
207. Rasoolinejad M, Haji-Abolbaghi M, Emami M, Zarchi M, Geramishoar M. Phaeohyphomycosis: cutaneous, subcutaneous, nasopharyngeal lesions. Acta Med Iranica 1999; 37: 30-33.
208. Djahromi SB, Kliaksar A, Iravani K. Phaeohyphomycosis of the sinuses and thorax by cladosporium bantianum. Mycoses 2002; 45(Suppl. 2): 3-72.
209. Saberi H, Kashfi A, Hamidi S, Tabatabai SA, Mansouri P. Cerebral phaeohyphomycosis masquerading as a parafalcian mass: case report. Surg Neurol 2003; 60(4): 354-359.
210. Geramishoar M, Zomorodian K, Zaini F, Saadat F, Tarazooie B, Norouzi M et al. First Case of Cerebral Phaeohyphomycosis Caused by Nattrassia mangiferae in Iran. Jpn J Infect Dis 2004; 57(6): 285-286.
211. Vitale RG, De Hoog GS, Verweij PE. In vitro activity of amphotericin B, itraconazole, terbinafine and 5-fluocytosine against Exophiala spinifera and evaluation of postantifungal effects. Med Mycol 2003; 41(4): 301-307.